Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Radiotherapy in Inoperable Stage I/II NSCLC
NCT00268255Phase 2Withdrawn
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00268255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268255.